Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 25, 2024

Pembrolizumab Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed High-Risk Endometrial Cancer

Annals of Oncology

 

Additional Info

Annals of Oncology
ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer
Ann. Oncol 2024 Sep 14;[EPub Ahead of Print], T Van Gorp, D Cibula, W Lv, F Backes, F Ortaç, K Hasegawa, K Lindemann, A Savarese, A Laenen, YM Kim, L Bodnar, MP Barretina-Ginesta, L Gilbert, B Pothuri, X Chen, MB Flores, T Levy, N Colombo, C Papadimitriou, T Buchanan, LC Hanker, G Eminowicz, L Rob, D Black, J Lichfield, G Lin, R Orlowski, S Keefe, A Lortholary, B Slomovitz

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading